Insulet (PODD) Akcie Kurz
Insulet Kurz
Tržby rostly o 41,6 % ročně za posledních 19 let na 2,71 Mld. USD. Zisk na akcii rostl o 81,5 % ročně za posledních 7 let. čistá marže společnosti Insulet je nyní 9,1 %, nahoru z 1,5 % před několika lety. Medián cílové ceny analytiků je 180,00 USD, tedy nad aktuální cenu o 33,9 %. Z 33 analytiků jich 20 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Insulet
Obchodní model Insulet a analýza akcií
Nejčastější otázky týkající se akcie Insulet
The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.
Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.
The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.
Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.
Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.
Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.
Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.
Analytici aktuálně stanovují průměrnou cílovou cenu 185,18 USD pro akcii Insulet (medián: 180,00 USD), tedy +37,7 % vůči poslední ceně. Konsensus vychází z 33 hodnocení analytiků.
33 analytiků aktuálně hodnotí akcii Insulet: 20 doporučuje koupit, 13 držet a 0 prodat. Pro rok 2026 analytici očekávají u Insulet tržby 3,29 Mld. USD a zisk na akcii 6,62 USD.
Při aktuálním kurzu se akcie Insulet obchoduje za 119,98 EUR (134,47 USD).
Akcie Insulet (PODD) je kótována na 5 burzách, mimo jiné: NASDAQ (PODD), SIX (Zürich) (GOV.SW), Frankfurt (GOV.F), München (GOV.MU), Düsseldorf (GOV.DU).
Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.
Tržby očekávané za Insulet činí 3,29 Mld. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Insulet činí 467,51 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Insulet je aktuálně 20,33. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Insulet.
Poměr ceny k tržbám (P/S) Insulet je aktuálně 2,89. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Insulet.
Score kvality pro Insulet je 6/10.
ISIN Insulet je US45784P1012. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Insulet je A0MQX8. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Insulet je PODD. Symbol tickeru se používá k obchodování akcií Insulet na burze.
Insulet akcie
Insulet Peer Group
Insulet Ticker
Insulet FIGI
Všechny fundamentální údaje o Insulet v podrobné analýze
Naše analýzy akcií společnosti Insulet zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Insulet. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: